

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



撥康視云™

Cloudbreak Pharma

CLOUDBREAK PHARMA INC.

撥康視雲製藥有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2592)

VOLUNTARY ANNOUNCEMENT

BUSINESS UPDATE

This announcement is made by Cloudbreak Pharma Inc. (the “**Company**”; together with its subsidiaries, the “**Group**”) on a voluntary basis for the purpose of keeping the shareholders and potential investors of the Company informed of the latest business development of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that Cloudbreak Therapeutics LLC (“**Cloudbreak USA**”), a wholly-owned subsidiary of the Company registered under the laws of California, the United States of America (the “**USA**”), has scheduled to meet with the United States Food and Drug Administration (the “**FDA**”) on 10 December 2025 at an End-of-Phase 2 (“**EOP2**”) meeting, in respect of CBT-004, one of the Clinical-Stage Drug Candidate.

As disclosed by the Company in its prospectus dated 24 June 2025 and in the interim report of the Group for the six months ended 30 June 2025:

CBT-004 is a potential first-in-class ophthalmic drug using Multi-Kinase Inhibitor targeting Vascular Endothelial Growth Factor Receptors and Platelet-Derived Growth Factor Receptors, indicated for the treatment of vascularised pterygia. The Group commenced Phase 2 clinical trial of CBT-004 in December 2023 and completed the trial in May 2025. The results indicated that CBT-004 was safe and well tolerated in subjects and met the primary endpoint and several secondary endpoints in efficacy. The Group completed the clinical trial report in July 2025 and plan to schedule an EOP2 meeting with the FDA in due course.

The Company considers the EOP2 meeting to be a significant milestone in the development of CBT-004, which discuss potential Phase 3 clinical trial development and New Drug Application requirements. The Company will make further announcement(s) to keep the shareholders and potential investors of the Company informed of the latest developments in relation to the Group’s business as and when appropriate.

Warning Statement: There is no guarantee that CBT-004 or any other Core Product of the Group will ultimately be successfully developed, launched or marketed.

Shareholders and potential investors of the Company should exercise caution and due care when dealing in the shares of the Company.

By order of the Board
Cloudbreak Pharma Inc.

Dr. NI Jinsong

Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, 8 December 2025

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Ni Jinsong, Mr. Dinh Son Van and Dr. Yang Rong as executive directors; (ii) Dr. Li Jun Zhi, Mr. Cao Xu and Mr. Xia Zhidong as non-executive directors; and (iii) Ms. Nie Sijiang, Mr. Ma Yiu Ho Peter and Mr. Lee Alex Jao Jang as independent non-executive directors.

* *For identification purpose only*